Results 21,521-21,540 of 33,581 for speaker:Catherine Connolly
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: I understand.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Would anyone have a bald figure on what that cost will be? It is clearly more than €32.1 million. Does anyone have an idea of what the cost will be, separate from the cost of rectifying and the new contracts?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: I understand that.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: For the first time, we are getting a clear idea of the cost of governance failure and a failure to act. This does not just apply to the HSE but applies to all organisations. We are getting a clearer idea of what would be cheaper and more effective. To return to governance and disclosure, there was a voluntary disclosure policy. Legislation was introduced and enacted very late. That is...
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: I have a note somewhere - I think it is from Mr. Breen - stating a process of setting up a national office for open disclosure has commenced and the State Claims Agency has been invited to sit on the interview panel. Am I wrong about that?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: That is where that is coming from. Is it happening speedily enough?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: When are the interviews?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: In Mr. Breen's opening statement, he referred to a protocol and the necessity for a pre-action protocol for medical negligence cases. Has that been done?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Will Mr. Breen clarify that for me?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: I have the document here. It refers to a pre-action protocol relating to clinical negligence and the making of regulations. Have the regulations been made?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Where does the fault lie for that?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Why have they not been made before now?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: How long will it take?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: We see so many good recommendations and reports and then there are delays in rolling them out. I ask the Chairman to indicate when I have five minutes left because I want to ask a number of questions on the thalidomide issue. A very good report was done by the Comptroller and Auditor General in 2012 on the clinical indemnity scheme. The issues raised then are very much alive today. One...
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: An overall figure was given.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Those costs would not be identified then.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: There was a recommendation that there should be a system of spot-checking. Has that happened?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: What is the result?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: They are actual savings made.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: There are savings of 48% in 2017, which we have not looked at yet. We have looked at the figures for 2016. Mr. Breen is saying these are actual savings in legal costs.